Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome

Immunosuppresive therapy in low risk myelodysplastic syndrome can achieve sustained hematologic improvement but is underutilized due to lack of selection criteria. We completed a retrospective analysis of sixty-six patients treated with immunosuppressive therapy to investigate treatment outcome and clinical co-variables that influence response. Overall hematologic improvement was 42%, comparable to other treatment options for lower risk MDS. The response rate was higher in low risk disease, treated early on in the disease process with immunosuppressive therapy as the first line treatment.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Mintallah Haider, Najla Al Ali, Eric Padron, Pearlie Epling-Burnette, Jeffrey Lancet, Alan List, Rami Komrokji Tags: SOHO Supplement 2016 Source Type: research